In 2010, we wrote an Annals editorial on a study using polyvalent intravenous immunoglobulin (IVIg) to treat complex regional pain syndrome (CRPS) (1). That study, a randomized controlled crossover trial of low-dose IVIg (0.5 g/kg of body weight) in patients with CRPS, was conducted after the authors observed IVIg's effectiveness in single patients (2). The results showed that pain was reduced during the treatment period, but because this pilot study included only a few patients treated at a single center, our 2010 editorial expressed both hope and doubt (1): hope, because immune mechanisms in CRPS pathophysiology were demonstrated, and we believed this knowledge might offer a window for targeted therapy, such as an effective anti-inflammatory treatment, with minor side effects; doubt, because of the preliminary character of the study. Furthermore, the multifaceted pathophysiology of chronic CRPS, which includes biological, psychiatric, and social components, as well as the immune mechanisms, diminishes the changes of success of a unimodal treatment.

在2010年，我们撰写了一份年鉴一篇关于使用多价静脉免疫球蛋白（IVIg）治疗复杂的区域性疼痛综合征（CRPS）的研究的社论（1）。在作者观察到IVIg对单例患者的有效性后，进行了这项针对CRPS患者的低剂量IVIg（0.5 g / kg体重）的随机对照交叉试验（2）。结果表明，在治疗期间疼痛有所减轻，但是由于该初步研究仅包括在单个中心接受治疗的少数患者，因此我们的2010年社论表达了希望和怀疑（1）：希望，因为已证明了CRPS病理生理学中的免疫机制，而且我们相信，这些知识可能会为靶向治疗（例如有效的消炎治疗）带来轻微副作用提供一个窗口；怀疑，因为该研究的初步性质。此外，